The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B-Reference-Cited by-同舟云学术

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B

Published:2021-10 Issue:7 Volume:5 Page:
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Sun Haowei (Linda)¹^ORCID,Yang Ming²,Poon Man‐Chiu³,Lee Adrienne³,Robinson K. Sue⁴,Sholzberg Michelle⁵^ORCID,Wu John⁶,Iorio Alfonso⁷^ORCID,Blanchette Victor⁸,Carcao Manuel⁸,Klaassen Robert J.⁹,Jackson Shannon²¹⁰

Affiliation:

1. Division of Hematology Department of Medicine University of Alberta Edmonton Alberta Canada

2. British Columbia Hemophilia Treatment Centre ‐ Adult Division Vancouver British Columbia Canada

3. Department of Medicine Foothills Medical Centre Cumming School of Medicine University of Calgary Calgary Alberta Canada

4. Division of Hematology Department of Medicine University of Dalhousie Halifax Nova Scotia Canada

5. Division of Hematology Departments of Medicine and Laboratory Medicine & Pathobiology St. Michael's Hospital Toronto Ontario Canada

6. Division of Hematology Oncology British Columbia Children and Women's Hospital Vancouver British Columbia Canada

7. Division of Hematology Department of Medicine McMaster University Hamilton Ontario Canada

8. Division of Hematology/Oncology Department of Pediatrics The Hospital for Sick Children University of Toronto Toronto Ontario Canada

9. Division of Hematology Oncology Department of Pediatrics Children's Hospital of Eastern Ontario Research Institute Ottawa Ontario Canada

10. Division of Hematology Department of Medicine University of British Columbia Vancouver British Columbia Canada

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12601

Reference27 articles.

1. WFH Guidelines for the Management of Hemophilia, 3rd edition

2. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes

3. Integrating response shift into health-related quality of life research: a theoretical model

4. Patient‐relevant health outcomes for hemophilia care: development of an international standard outcomes set;Balen EC;Res Pract Thromb Haemost,2020

5. The MOS 36-ltem Short-Form Health Survey (SF-36)

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A;Drugs - Real World Outcomes;2024-08-10

2. Reduced Volume and Faster Infusion Rate of Activated Prothrombin Complex Concentrate: A Phase 3b/4 Trial in Adults with Hemophilia A with Inhibitors;TH Open;2024-07

3. Perioperative Management of Hemophilia Patients;Current Anesthesiology Reports;2024-06-14

4. The Evolution of Hemophilia Therapeutics: An Illustrated Review;Research and Practice in Thrombosis and Haemostasis;2024-03

5. Recombinant factor IX Fc for the treatment of hemophilia B;European Journal of Haematology;2024-02-18